Drug-Resistant Tuberculosis and COVID-19: A Scoping Review on a New Threat to Antimicrobial Resistance.


Journal

Revista brasileira de enfermagem
ISSN: 1984-0446
Titre abrégé: Rev Bras Enferm
Pays: Brazil
ID NLM: 7910105

Informations de publication

Date de publication:
2023
Historique:
received: 17 02 2023
accepted: 14 08 2023
medline: 11 12 2023
pubmed: 6 12 2023
entrez: 6 12 2023
Statut: epublish

Résumé

To assess the impact of COVID-19 on the morbidity and mortality associated with drug-resistant tuberculosis (DR-TB). A comprehensive review of articles published in international databases since December 2019 was conducted. The findings are presented in a narrative format, supplemented with tables, diagrams, and a map created using ArcGIS software. Thirty-five studies were selected, highlighting the significant consequences of COVID-19 on TB and DR-TB treatment progress. Four main thematic areas were identified: Clinical and epidemiological aspects of the interaction between COVID-19 and DR-TB; Management of physical resources and the team; Challenges and circumstances; Perspectives and possibilities. This study revealed that the COVID-19 pandemic significantly negatively impacted the control of long-standing diseases like TB, particularly in the context of morbidity and mortality related to DR-TB.

Identifiants

pubmed: 38055430
pii: S0034-71672023000300303
doi: 10.1590/0034-7167-2022-0803
pmc: PMC10695069
pii:
doi:

Substances chimiques

Antitubercular Agents 0

Types de publication

Review Journal Article

Langues

eng por

Pagination

e20220803

Références

Rev Soc Bras Med Trop. 2021 Jul 23;54:e00902021
pubmed: 34320129
Disaster Med Public Health Prep. 2020 Aug;14(4):e9-e10
pubmed: 32635960
Int J Evid Based Healthc. 2015 Sep;13(3):141-6
pubmed: 26134548
J Multidiscip Healthc. 2022 Jan 26;15:175-183
pubmed: 35115781
Int J Gynaecol Obstet. 2021 Apr;153(1):176-179
pubmed: 33421126
BMC Infect Dis. 2020 Oct 9;20(1):744
pubmed: 33036570
J Bras Pneumol. 2020;46(2):e20190290
pubmed: 32402012
Int J Tuberc Lung Dis. 2021 Sep 1;25(9):772-775
pubmed: 34802503
J Med Virol. 2021 Jan;93(1):194-196
pubmed: 32687228
Nat Rev Microbiol. 2020 Aug;18(8):409-410
pubmed: 32488173
Infect Drug Resist. 2022 Aug 29;15:4971-4984
pubmed: 36060232
Int J Infect Dis. 2021 Jul;108:557-567
pubmed: 34139370
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Rev Bras Enferm. 2020 Mar 30;73(2):e20180668
pubmed: 32236372
Lancet Respir Med. 2021 Jun;9(6):556-558
pubmed: 33773121
ERJ Open Res. 2020 Nov 02;6(4):
pubmed: 33263043
J Intern Med. 2021 Apr;289(4):589-590
pubmed: 33078450
BMJ Open. 2022 Feb 8;12(2):e053290
pubmed: 35135769
J Family Med Prim Care. 2021 Oct;10(10):3922-3924
pubmed: 34934706
Int J Tuberc Lung Dis. 2020 Jul 1;24(7):747-749
pubmed: 32718415
Eur Respir J. 2020 Jul 23;56(1):
pubmed: 32471936
BMC Med Res Methodol. 2018 Nov 19;18(1):143
pubmed: 30453902
Am J Trop Med Hyg. 2020 Nov;103(5):1986-1988
pubmed: 32978934
Med J Armed Forces India. 2021 Jul;77:S479-S482
pubmed: 34334915
Lancet Infect Dis. 2022 Jul;22(7):e191-e196
pubmed: 35248168
Pulmonology. 2021 Jan-Feb;27(1):67-69
pubmed: 32561353
Euro Surveill. 2021 Jun;26(24):
pubmed: 34142649
Lancet Respir Med. 2020 Oct;8(10):950-952
pubmed: 33007284
Front Microbiol. 2021 Feb 04;12:612675
pubmed: 33613483
Int J Infect Dis. 2021 Oct;111:322-325
pubmed: 34508864
Elife. 2021 Feb 16;10:
pubmed: 33588991
BMC Health Serv Res. 2021 Oct 1;21(1):1033
pubmed: 34592970
Pathogens. 2022 Feb 01;11(2):
pubmed: 35215139
Int J Infect Dis. 2021 Dec;113 Suppl 1:S96-S99
pubmed: 33713815
Med Sci Monit. 2021 Aug 09;27:e934292
pubmed: 34366429
Int J Tuberc Lung Dis. 2020 Oct 1;24(10):1119-1121
pubmed: 33126951
BMC Med Res Methodol. 2016 Feb 09;16:15
pubmed: 26857112
Pulmonology. 2021 May-Jun;27(3):248-256
pubmed: 33547028
Lancet Child Adolesc Health. 2021 Mar;5(3):159-161
pubmed: 33609490
PLoS One. 2021 Apr 9;16(4):e0249822
pubmed: 33836024
Infect Dis Poverty. 2021 Mar 25;10(1):41
pubmed: 33766122
Rev Bras Enferm. 2020 Apr 03;73(3):e20180453
pubmed: 32267414
Emerg Infect Dis. 2022 Mar;28(3):684-692
pubmed: 35202526
Rev Panam Salud Publica. 2019 Dec 20;43:e102
pubmed: 31892928
Pulmonology. 2021 Mar-Apr;27(2):94-96
pubmed: 33272908

Auteurs

Beibilene Perlato Melo da Silva (BPMD)

Universidade Federal de São Carlos. São Carlos, São Paulo, Brazil.

Anelisa Soares de Almeida (AS)

Universidade Federal de São Carlos. São Carlos, São Paulo, Brazil.

Matheus Gabriel de Melo Sérgio (MGM)

Universidade Federal de São Carlos. São Carlos, São Paulo, Brazil.

Thamires Carraro Gatto (TC)

Universidade Federal de São Carlos. São Carlos, São Paulo, Brazil.

Vinícius Paglione Carasek (VP)

Universidade Federal de São Carlos. São Carlos, São Paulo, Brazil.

Mellina Yamamura (M)

Universidade Federal de São Carlos. São Carlos, São Paulo, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH